骨肿瘤的新兴治疗:来自 ESMO 年会的经验教训
Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting.
原发性骨肉瘤是罕见的异质性恶性肿瘤,治疗选择有限,尤其是在转移性疾病中,预后仍然很差。
78.4分
★★★★☆
ALL SOURCES
Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting.
原发性骨肉瘤是罕见的异质性恶性肿瘤,治疗选择有限,尤其是在转移性疾病中,预后仍然很差。
Therapeutic advances in the targeting of ROR1 in hematological cancers.
受体酪氨酸激酶(RTK)是参与细胞通讯和信号转导的关键细胞表面受体,在细胞生长、分化、存活和代谢中极为重要。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。